MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

A

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

Search

CIDARA THERAPEUTICS INC

Open

SectorGezondheidszorg

221.38 0.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

221.38

Max

221.38

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-1.98% downside

Nieuwssentiment

By Acuity

27%

73%

73 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

CIDARA THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal -- Update

14 nov 2025, 12:16 UTC

Acquisities, Fusies, Overnames

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

14 nov 2025, 11:20 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Cidara Shares Nearly Double Premarket on Report of Takeover by Merck

14 nov 2025, 11:11 UTC

Acquisities, Fusies, Overnames

Merck Nears $9.2 Billion Deal for Cidara, FT Reports, Citing Sources

23 jun 2025, 12:05 UTC

Belangrijke Marktbewegers

Cidara Shares Soar Premarket After Positive Influenza Trial Results

7 jan 2026, 11:46 UTC

Acquisities, Fusies, Overnames

Merck: Nearly 86% of Cidara Shares Validly Tendered >MRK CDTX

7 jan 2026, 11:45 UTC

Acquisities, Fusies, Overnames

Merck To Complete Acquisition Of Cidara Therapeutics >MRK

14 nov 2025, 16:30 UTC

Acquisities, Fusies, Overnames

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov 2025, 13:19 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Is Soaring 100%. Merck Is Buying It. -- Barrons.com

14 nov 2025, 12:22 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Pharma Sector Becoming Bidding Battlefield -- Market Talk

Peer Vergelijking

Prijswijziging

CIDARA THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

-1.98% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 217 USD  -1.98%

Hoogste 221.5 USD

Laagste 199 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CIDARA THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

6 ratings

1

Buy

5

Hold

0

Sell

Technische score

By Trading Central

18.88 / 19.67Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

73 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

$

help-icon Live chat